secwatch.observer — SEC 8-K summary
======================================

Issuer:     Adia Nutrition, Inc. (ADIA)
CIK:        0001160420
Form:       8-K
Filed at:   2026-10-19T15:22:28+00:00
Accession:  0001683168-26-007951
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.35
Item codes: 1.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Adia Med sells 7% of Adia Labs LLC to CEO Larry Powalisz for $350,000 cash in related-party deal
--------------------------------------------------------------------------------

- Adia Med sold 7 of 100 units in subsidiary Adia Labs LLC to CEO Larry Powalisz for $350,000 cash, or $50,000 per unit, per the Oct 13, 2026 agreement.
- The units carry a 7% membership interest and 7% of total voting power (one vote per unit of 100); operating agreement to be amended at closing.
- Related-party terms: Powalisz buys as an individual; independent directors Monica Sher, M.D. and Richard Edwards, D.O. signed for Adia Med and must jointly approve in writing any use of the proceeds.
- Powalisz has no unilateral authority to direct spending of the purchase price or to approve/execute amendments on the seller's behalf.
- Closing needs full wire payment plus buyer joinder and updated cap table; deal terminates if not closed within 10 days of effectiveness. Live Oak Health (QCM Biologics) consented.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1160420/000168316826007951/0001683168-26-007951-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1160420/000168316826007951/adia_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-26-007951

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer